Mandate

Vinge advised Fortum Värme in connection with the Swedish Competition Authority’s three-year investigation regarding the price of district heating in Stockholm

November 15, 2010

Since October 2007 the Swedish Competition Authority has investigated whether Fortum Värme, jointly owned by Fortum and the City of Stockholm, abused a dominant position in breach of the Swedish Competition Act by imposing unfairly high prices (excessive pricing) on its district heating customers in the Stockholm area. The Competition Authority has, by its unconditional decision on 12 November 2010, now closed the extensive and detailed investigation without any further actions. Fortum Värme has, during the investigation, declared its intention to ensure, for 2011, that the revenues generated from its district heating operations in Stockholm do not exceed a revenue cap defined by the company.     

Vinge’s competition team included responsible partner Johan Karlsson and several associates, including Carl Johan Sundqvist and Emil Fahlén Godö. Part of the team was also associate professor Mattias Ganslandt who, inter alia, contributed with several economic reports concerning the market for district heating and Fortum Värme’s pricing.

The Swedish Competition Authority’s decision and press release

Related

Vinge has advised Hansa Biopharma in connection with entering into a financing agreement

Vinge has advised Hansa Biopharma AB (publ), a commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions, listed on Nasdaq Stockholm, in connection with a U.S. convertible note purchase agreement comprising USD 30 million aggregate principal amount of unsecured convertible senior notes.
March 23, 2026

Vinge advises in connection with data center provider EcoDataCenter’s tap issue of SEK 500 million bonds

Vinge has advised in connection with EcoDC Holding AB (publ)'s tap issue of SEK 500 million senior unsecured bonds under the existing framework of up to SEK 2 billion.
March 19, 2026

Vinge has advised Cinclus Pharma in connection with entering into financing agreement

Vinge has advised Cinclus Pharma Holding AB (publ), a late-stage clinical pharmaceutical company developing next-generation treatments for gastric acid-related diseases listed on Nasdaq Stockholm, in connection with a long-term structured credit agreement for a total of up to EUR 28 million divided into four tranches, of which two are convertibles.
March 16, 2026